OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3944 participants.

Also called NCT05418556

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,944 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05418556
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05418556. Randomized; no masking; primary purpose treatment. Start 2022-10-21 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation
Acronym
OPTIMIZE-APT
Intervention (Drug)
aspirin
Lead sponsor
Asan Medical Center (class: other)

Record details

Record id
cardio:ct-nct05418556
Content hash
21278e62280ca211212633d4a292428631ba11fe31d773499114e1f8def825ed